Outlook Therapeutics, Inc.

    Jurisdiction
    United States
    LEI
    5493007AWUJ6HPMCBH11
    ISIN
    US69012T3059 (OTLK)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 48 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €1.30M
    Gross margin
    70.8%
    EBIT
    -€62.68M
    EBIT margin
    -4,824.5%
    Net income
    -€37.49M
    Net margin
    -2,885.8%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €25.69M +1,877.3% -€36.61M -2.4%
    €62.18M +142.1% -€17.87M -51.2%
    €35.73M -42.5% -€20.50M +14.7%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 16, 2024

    Add to watchlist

    Notifications